Post-Transplant Lymphoproliferative Disease (PTLD): Risk Factors, Diagnosis, and Current Treatment Strategies
Top Cited Papers
- 5 June 2013
- journal article
- research article
- Published by Springer Science and Business Media LLC in Current Hematologic Malignancy Reports
- Vol. 8 (3), 173-183
- https://doi.org/10.1007/s11899-013-0162-5
Abstract
Post-transplant lymphoproliferative diseases (PTLD) are heterogeneous lymphoid disorders ranging from indolent polyclonal proliferations to aggressive lymphomas that complicate solid organ or hematopoietic transplantation. Risk factors for PTLD include viral infections, degree of immunosuppression, recipient age and race, allograft type, and host genetic variations. Clinically, extra-nodal disease is common including 10–15 % presenting with central nervous system (CNS) disease. Most PTLD cases are B cell (5-10 % T/NK cell or Hodgkin lymphoma), while over one-third are EBV-negative. World Health Organization (WHO) diagnostic categories are: early lesions, polymorphic, and monomorphic PTLD; although in practice, a clear separation is not always possible. Therapeutically, reduction in immunosuppression remains a mainstay, and recent data has documented the importance of rituximab +/- combination chemotherapy. Therapy for primary CNS PTLD should be managed according to immunocompetent CNS paradigms. Finally, novel treatment strategies for PTLD have emerged, including adoptive immunotherapy and rational targeted therapeutics (e.g., anti-CD30 based therapy and downstream signaling pathways of latent membrane protein-2A).Keywords
This publication has 106 references indexed in Scilit:
- A shared gene expression signature in mouse models of EBV-associated and non–EBV-associated Burkitt lymphomaBlood, 2011
- Association of HLA Polymorphisms with Post-transplant Lymphoproliferative Disorder in Solid-Organ Transplant RecipientsAmerican Journal of Transplantation, 2011
- Reduction of Immunosuppression as Initial Therapy for Posttransplantation Lymphoproliferative Disorder★American Journal of Transplantation, 2011
- Multicenter Analysis of 80 Solid Organ Transplantation Recipients With Post-Transplantation Lymphoproliferative Disease: Outcomes and Prognostic Factors in the Modern EraJournal of Clinical Oncology, 2010
- Tumour necrosis factor gene polymorphism: a predictive factor for the development of post-transplant lymphoproliferative diseaseBritish Journal of Cancer, 2009
- Epstein-Barr Virus Latent Membrane Protein 2A Preferentially Signals through the Src Family Kinase LynJournal of Virology, 2008
- Prospective phase II trial of extended treatment with rituximab in patients with B-cell post-transplant lymphoproliferative diseaseHaematologica, 2007
- Dissociation of Depletional Induction and Posttransplant Lymphoproliferative Disease in Kidney Recipients Treated With AlemtuzumabAmerican Journal of Transplantation, 2007
- Epstein-Barr Virus Latent Membrane Protein 2A Mediates Transformation through Constitutive Activation of the Ras/PI3-K/Akt PathwayJournal of Virology, 2007
- A phase 1/2 trial of arginine butyrate and ganciclovir in patients with Epstein-Barr virus–associated lymphoid malignanciesBlood, 2006